Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01130584|
Recruitment Status : Completed
First Posted : May 26, 2010
Last Update Posted : December 11, 2013
The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer.
Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.
|Condition or disease||Intervention/treatment|
|Cancer||Other: Pyruvate kinase isoform M2|
|Study Type :||Observational|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||April 2013|
|Actual Study Completion Date :||April 2013|
Other: Pyruvate kinase isoform M2
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01130584
|National University Hospital, Singapore|